Stock R5W STEM CELL THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Analyst Reco. Stem Cell Therapeutics Corp. Xetra

Equities

R5W

CA8585721001

End-of-day quote Xetra
Other stock markets
- EUR - Intraday chart for Stem Cell Therapeutics Corp.
2022 TCR2 Therapeutics Appoints Chief Business and Strategy Officer MT
2021 Pfizer Deploying Some of Its Covid Cash in Arena Deal -- Analysis DJ

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Benchmark Downgrades Trillium Therapeutics to Hold From Buy
MT
TRILLIUM THERAPEUTICS : Benchmark Adjusts Price Target for Trillium Therapeutics to C$23.34 From C$26.41, Maintains Buy Rating
MT
Today on Wall Street: A new central bank theory
Our Logo
TRILLIUM THERAPEUTICS : Craig-Hallum Downgrades Trillium Therapeutics to Hold From Buy
MT
TRILLIUM THERAPEUTICS : JMP Securities Downgrades Trillium Therapeutics to Market Perform From Market Outperform
MT
ANALYST RECOMMENDATIONS : M&S, Estee Lauder, Planet Fitness, Snowflake, Steel Dynamics...
Our Logo
TRILLIUM THERAPEUTICS : HC Wainwright Downgrades Trillium Therapeutics to Neutral From Buy, Adjusts Price Target to $18.50 From $22
MT
TRILLIUM THERAPEUTICS : Benchmark Starts Trillium Therapeutics at Buy With $21 Price Target
MT
TRILLIUM THERAPEUTICS : HC Wainwright Adjusts Trillium Therapeutics' Price Target to $22 From $16.50, Keeps at Buy
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRIL Stock
  4. R5W Stock
  5. News Stem Cell Therapeutics Corp.
  6. Analyst Reco.